Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD69 | Q07108 | 1/20 | 0.60 |
| ▸ | LGALS3 | P17931 | 6/20 | 0.60 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.60 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.60 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.50 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.50 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-Acetylchitopentaose SCHEMBL20390680 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| Chitodextrin SCHEMBL619917 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| Triacetylchitotriose SCHEMBL425647 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| Chitodextrin SCHEMBL19427436 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| Triacetylchitotriose SCHEMBL974524 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| Chitodextrin SCHEMBL619918 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| Triacetylchitotriose SCHEMBL13040980 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| SCHEMBL20390674 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| Chitodextrin SCHEMBL21067311 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| Chitodextrin SCHEMBL7269765 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240058456-A1 | MOLECULES WITH SOLUBILITY TAG AND RELATED METHODS | MERCK KGAA (DE) | 2024-02-22 | — | — | US | disclosed |
| US-20220143059-A1 | COMPOSITIONS AND THERAPEUTIC METHODS | AYUVIS RESEARCH, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11207343-B2 | Compositions and therapeutic methods | AYUVIS RESEARCH, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20170281667-A1 | NOVEL COMPOSITIONS AND THERAPEUTIC METHODS | AYUVIS RESEARCH, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170281667-A1 | NOVEL COMPOSITIONS AND THERAPEUTIC METHODS | AYUVIS RESEARCH, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20140295566-A1 | CARBOHYDRATE-LIGAND CONJUGATES AND THEIR APPLICATION FOR THE ANALYSIS OF CARBOHYDRATE-PROTEIN INTERACTION | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-02 | — | — | US | disclosed |
| US-7838549-B2 | Linker compound, ligand conjugate, and production methods thereof | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-11-23 | — | — | US | disclosed |
| US-20100204464-A1 | ASCORBIC ACID DERIVATIVES, THEIR PREPARATION METHODS, INTERMEDIATES AND USES IN COSMETICS | NANJING ZHONGSHI CHEMICAL CO., LTD. (CN) | 2010-08-12 | — | — | US | disclosed |
| US-20100204464-A1 | ASCORBIC ACID DERIVATIVES, THEIR PREPARATION METHODS, INTERMEDIATES AND USES IN COSMETICS | NANJING ZHONGSHI CHEMICAL CO., LTD. (CN) | 2010-08-12 | — | — | US | disclosed |
| US-20070213523-A1 | Linker Compound, Ligand Conjugate, and Production Methods Thereof | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11207343-B2 | Compositions and therapeutic methods | RB1, TNF, FLT1 | CD69 1566/4885LGALS3 2453/4885LGALS8 2627/4885 |
| US-20070213523-A1 | Linker Compound, Ligand Conjugate, and Production Methods Thereof | SLC7A5, SLC2A1, SLC2A9 | CD69 2204/4885LGALS3 2161/4885LGALS8 1029/4885 |
| US-20220143059-A1 | COMPOSITIONS AND THERAPEUTIC METHODS | RB1, FLT1, FLT4 | CD69 429/4885LGALS3 2431/4885LGALS8 2459/4885 |
| US-20170281667-A1 | NOVEL COMPOSITIONS AND THERAPEUTIC METHODS | RB1, CD47, FLT1 | CD69 1769/4885LGALS3 2319/4885LGALS8 2553/4885 |
| US-20100204464-A1 | ASCORBIC ACID DERIVATIVES, THEIR PREPARATION METHODS, INTERMEDIATES AND USES IN COSMETICS | AGL, UGCG, UGGT1 | CD69 3323/4885LGALS3 305/4885LGALS8 783/4885 |
| US-20140295566-A1 | CARBOHYDRATE-LIGAND CONJUGATES AND THEIR APPLICATION FOR THE ANALYSIS OF CARBOHYDRATE-PROTEIN INTERACTION | CA11, CA14, OSTC | CD69 2734/4885LGALS3 163/4885LGALS8 175/4885 |
| US-20240058456-A1 | MOLECULES WITH SOLUBILITY TAG AND RELATED METHODS | STT3B, STT3A, CD2BP2 | CD69 172/4885LGALS3 463/4885LGALS8 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.